BETWEENResearch, Development and Commercialization Agreement • November 9th, 2006 • EPIX Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Maryland
EX-10.10 16 d562658dex1010.htm EX-10.10 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Execution Version RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and...Research, Development and Commercialization Agreement • May 5th, 2020 • New York
This Agreement (the “Agreement”) is made as of the 31st day of July, 2012 (the “Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605 (“LLS”) and Constellation Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 215 First Street, Suite 200, Cambridge, MA 02142 (“Company”). LLS and Company are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RESEARCH, DEVELOPMENT AND...Research, Development and Commercialization Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • Delaware
This Agreement (this “Agreement”) is made on this 1st day of May, 2018 and shall be effective on the Effective Date by and between Icagen, Inc. (“Icagen”), a corporation having a principal place of business at [***] acting on behalf of itself and Affiliates, and Cystic Fibrosis Foundation (“CFF”), a nonprofit corporation with its principal offices at [***], and shall become effective on the Effective Date. Icagen and CFF are each referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. RESEARCH, DEVELOPMENT AND...Research, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations • Massachusetts
This Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Amendment No. 7 Research,...Research, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
Whereas, Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation (“CFFT”), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), are parties to that certain Research, Development and Commercialization Agreement dated May 24, 2004, as previously amended by Amendment No. 1 thereto dated January 6, 2006, Amendment No. 2 thereto dated as of January 1, 2006, Amendment No. 3 thereto dated November 20, 2006, Amendment No. 4 thereto dated August 20, 2007, Amendment No. 5 thereto dated as of April 1, 2011, and Amendment No. 6 thereto dated March 29, 2012 (collectively, the “Agreement”). Capitalized terms used herein without specific definition shall have the meanings set forth in the Agreement.
Confidential Treatment Requested Confidential portions of this document have been redacted and have been separately filed with the Commission RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and Cystic...Research, Development and Commercialization Agreement • August 19th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
EX-10.1 2 sgmo-ex101_20150331717.htm EX-10.1 EXECUTION COPY RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Sangamo BioSciences, Inc. and Juvenile Diabetes Research Foundation International pageResearch, Development and Commercialization Agreement • May 5th, 2020 • Delaware
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. Amendment No. 7 Research,...Research, Development and Commercialization Agreement • November 3rd, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
Whereas, Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation (“CFFT”), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), are parties to that certain Research, Development and Commercialization Agreement dated May 24, 2004, as previously amended by Amendment No. 1 thereto dated January 6, 2006, Amendment No. 2 thereto dated as of January 1, 2006, Amendment No. 3 thereto dated November 20, 2006, Amendment No. 4 thereto dated August 20, 2007, Amendment No. 5 thereto dated as of April 1, 2011, and Amendment No. 6 thereto dated March 29, 2012 (collectively, the “Agreement”). Capitalized terms used herein without specific definition shall have the meanings set forth in the Agreement.
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. RESEARCH, DEVELOPMENT AND...Research, Development and Commercialization Agreement • November 3rd, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
AMENDMENT NO. 2 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATEDResearch, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDMENT NO. 1 TO RESEARCH,...Research, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) is made this 6th day of January, 2006 (the “Effective Date”) between Vertex, a Massachusetts corporation with principal offices at 130 Waverly Street, Cambridge, MA 02139-4242 and CFFT, a Delaware corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814. Vertex and CFFT are referred to hereinafter collectively as the Parties.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDMENT NO. 5 to RESEARCH,...Research, Development and Commercialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 5 (the “Fifth Amendment”) is made effective as of April 1, 2011 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
EX-10.1 4 d918922dex101.htm EX-10.1Research, Development and Commercialization Agreement • May 5th, 2020 • Massachusetts
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
EX-10.24C 5 dex1024c.htm AMENDED AND RESTATED AGREEMENT RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTResearch, Development and Commercialization Agreement • May 5th, 2020
This Amended and Restated Research, Development and Collaboration Agreement (this “Agreement”) is effective as of July 1, 2008 (the “Effective Date”) by and between Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware corporation with offices at 4650 Horton Street, Emeryville, California 94608 (together with its Affiliates, “NVDI”), and XOMA (US) LLC, a Delaware limited liability company with offices at 2910 Seventh Street, Berkeley, California 94710 (together with its Affiliates, “XOMA”). NVDI and XOMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” When used in this Agreement, capitalized terms shall have the meanings set forth in Article 1.
AMENDMENT NO. 2 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATEDResearch, Development and Commercialization Agreement • August 19th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS([*]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE EXCHANGE ACT OF 1934, AS AMENDED RESEARCH,...Research, Development and Commercialization Agreement • June 5th, 2006 • Combinatorx, Inc • Pharmaceutical preparations • Maryland
THIS RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made this day of May, 2006, (the “Effective Date”) (the “Agreement”), by and between CombinatoRx, Incorporated (“CombinatoRx”), a Delaware corporation with principal offices at 245 First Street, Cambridge, MA, 02142 (“CombinatoRx”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Maryland corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”). CombinatoRx and CFFT may each be referred to as a “party” and collectively, as the “Parties.”
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between EPIX Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc.Research, Development and Commercialization Agreement • May 9th, 2008 • EPIX Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
This Agreement (as defined below) is made as of this 1st day of April, 2008 (the “Effective Date”) by and between EPIX Pharmaceuticals, Inc. (“EPIX”), a Delaware corporation with its principal office at 4 Maguire Road, Lexington, MA 02421, and Cystic Fibrosis Foundation Therapeutics, Inc., a Maryland corporation with its principal offices at 6931 Arlington Road, Bethesda, MD 20814 (“CFFT”), and shall become effective on the Effective Date (as defined below). EPIX and CFFT are each a “Party,” and, collectively, the “Parties.”
FIRST AMENDMENT TO RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SANGAMO BIOSCIENCES, INC. (“SANGAMO”) AND JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL (“JDRF”)Research, Development and Commercialization Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This First Amendment (this “First Amendment”) to the Agreement of October 24, 2006 is made as of this 8th day of January 2010 (the “First Amendment Effective Date”) by and between Sangamo and JDRF. Capitalized terms used but not defined herein shall have the definition provided in this Agreement.
Third Amendment to Research Development and Commercialization Agreement Between EPIX Pharmaceuticals, Inc. (“EPIX”) and Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”)Research Development and Commercialization Agreement • November 7th, 2007 • EPIX Pharmaceuticals, Inc. • Pharmaceutical preparations
This Third Amendment (this “Third Amendment”) to the Agreement of March 7, 2005 (as amended, the “Agreement”) is made as of this first day of November, 2007 (the “Effective Date”), by and between EPIX (as successor-in-interest to Predix) and CFFT. Capitalized terms used but not defined herein shall have the definition provided in the Agreement.
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Sangamo BioSciences, Inc. and Juvenile Diabetes Research Foundation InternationalResearch, Development and Commercialization Agreement • March 1st, 2007 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement (this “Agreement”) is made on this 24th day of October, 2006, by and between Sangamo BioSciences, Inc., a Delaware corporation, with its principal office at 501 Canal Boulevard, Suite A100, Richmond, CA 94804 (“Sangamo”) and Juvenile Diabetes Research Foundation International, a Pennsylvania nonprofit corporation with its principal offices at 120 Wall Street, New York, NY 10005 (“JDRF”). This Agreement shall become effective on the Effective Date (as defined below). Sangamo and JDRF are each a “Party,” and, collectively, the “Parties.”
ANDResearch, Development and Commercialization Agreement • March 2nd, 1999 • Clontech Laboratories Inc • Biological products, (no disgnostic substances) • California
October 19, 2018 Proteostasis Therapeutics, Inc.Research, Development and Commercialization Agreement • March 8th, 2019 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTResearch, Development and Commercialization Agreement • December 23rd, 2008 • Via Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Research, Development and Commercialization Agreement (“Agreement”) is signed as of this 18th day of December, 2008, by and between:
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. RESEARCH, DEVELOPMENT AND...Research, Development and Commercialization Agreement • September 29th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations • Massachusetts
This Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
indicates that a confidential portion of the text of this agreement has been omitted. AMENDMENT NO. 1 TO AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTResearch, Development and Commercialization Agreement • March 14th, 2012 • XOMA Corp • Pharmaceutical preparations
This Amendment No. 1 to Amended and Restated Research, Development and Commercialization Agreement (this “Amendment”) is effective as of April 30, 2010 (the “Amendment Effective Date”) by and between Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware corporation with offices at 4650 Horton Street, Emeryville, California 94608 (together with its Affiliates, “NVDI”), and XOMA (US) LLC, a Delaware limited liability company with offices at 2910 Seventh Street, Berkeley, California 94710 (together with its Affiliates, “XOMA”). NVDI and XOMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” When used in this Amendment, capitalized terms shall have the meanings set forth in Article 1 of the Amended and Restated Agreement (as defined below).
AMENDMENT NO. 2 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATEDResearch, Development and Commercialization Agreement • September 29th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDMENT NO. 1 TO RESEARCH,...Research, Development and Commercialization Agreement • September 29th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) is made this 6th day of January, 2006 (the “Effective Date”) between Vertex, a Massachusetts corporation with principal offices at 130 Waverly Street, Cambridge, MA 02139-4242 and CFFT, a Delaware corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814. Vertex and CFFT are referred to hereinafter collectively as the Parties.
AMENDMENT NO. 5 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORPORATEDResearch, Development and Commercialization Agreement • November 3rd, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Amendment No. 5 (the “Fifth Amendment”) is made effective as of April 1, 2011 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDMENT NO. 5 to RESEARCH,...Research, Development and Commercialization Agreement • September 29th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations
This Amendment No. 5 (the “Fifth Amendment”) is made effective as of April 1, 2011 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
Confidential Treatment Requested Confidential portions of this document have been redacted and have been separately filed with the Commission AMENDMENT NO. 5 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between...Research, Development and Commercialization Agreement • August 9th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Amendment No. 5 (the “Fifth Amendment”) is made effective as of April 1, 2011 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission AMENDMENT NO. 2 toResearch, Development and Commercialization Agreement • May 10th, 2006 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Amendment No. 2 (the “Second Amendment”) is made as of January 1, 2006 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with its principal offices at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 (“Vertex”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation with its principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”).
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTResearch, Development and Commercialization Agreement • December 23rd, 2008 • Via Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 18th day of December, 2008, by and between:
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission AMENDMENT NO. 1 TO RESEARCH, DEVELOPMENT AND COMMECIALIZATION AGREEMENT (the "Existing Agreement") DATED MAY...Research, Development and Commercialization Agreement • March 16th, 2006 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Amendment No. 1 (the "Amendment") is made this 6th day of January, 2006 (the "Effective Date") between Vertex, a Massachusetts corporation with principal offices at 130 Waverly Street, Cambridge, MA 02139-4242 and CFFT, a Delaware corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814. Vertex and CFFT are referred to hereinafter collectively as the Parties.
ContractResearch, Development and Commercialization Agreement • November 6th, 2015 • XOMA Corp • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
EX-10.5 3 a16-17137_1ex10d5.htm EX-10.5 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTResearch, Development and Commercialization Agreement • May 5th, 2020 • Delaware
This Research, Development and Commercialization Agreement (“Agreement”) is entered into as of this 18th day of December, 2008, by and between:
